別品名 |
Butanedioic acid, mono(3-butyl-8-(9-carboxy-6- hydroxy-3,7-dimethyl-2,4,8-nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7-dioxaspiro(5.5)undec-3-yl) ester
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
660.79
|
CAS RN® |
134615-37-5
|
化合物の概要 |
Isoleucyl-tRNA synthase inhibitor, osteoclast protein synthesis inhibitor.
|
構造 |
C36H52O11
|
溶媒 |
Soluble in DMF, DMSO, ethanol, ethyl acetate or methanol.
|
使用目的 |
Reveromycin A is an osteoclast-targeting antibiotic compound that exhibits anti-resorptive and antifungal activities. In animal models of juvenile Paget’s disease, reveromycin A inhibits bone resorption and normalizes bone turnover and formation. Reveromycin A inhibits isoleucyl-tRNA synthase, preventing protein synthesis in osteoclasts; this induces apoptosis and prevents resorption in vivo. Additionally, reveromycin A inhibits bone metastasis by lung cancer cells.
|
その他 |
[融点]95℃
|
参考文献 |
Yabumoto T, Miyazawa K, Tabuchi M, et al. Stabilization of tooth movement by administration of reveromycin A to osteoprotegerin-deficient knockout mice. Am J Orthod Dentofacial Orthop. 2013 Sep;144(3):368-80. PMID: 23992809.Hiraoka K, Zenmyo M, Watari K, et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 2008 Aug;99(8):1595-602. PMID: 18754872.Woo JT, Kawatani M, Kato M, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34. PMID: 16537392.
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
メーカー |
品番 |
包装 |
LKT
|
R1985
|
100 UG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
-20℃
|
|